MA38699B1 - Formulation orale pour le traitement de maladies cardiovasculaires - Google Patents

Formulation orale pour le traitement de maladies cardiovasculaires

Info

Publication number
MA38699B1
MA38699B1 MA38699A MA38699A MA38699B1 MA 38699 B1 MA38699 B1 MA 38699B1 MA 38699 A MA38699 A MA 38699A MA 38699 A MA38699 A MA 38699A MA 38699 B1 MA38699 B1 MA 38699B1
Authority
MA
Morocco
Prior art keywords
treatment
cardiovascular diseases
oral formulation
statin
acetylsalicylic acid
Prior art date
Application number
MA38699A
Other languages
English (en)
Other versions
MA38699A1 (fr
Inventor
Sanz Pablo Martin
Hurtado Javier Urbano
Original Assignee
Ferrer Int
Fundación Centro Nac De Investigaciones Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38699(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int, Fundación Centro Nac De Investigaciones Cardiovasculares Carlos Iii filed Critical Ferrer Int
Publication of MA38699A1 publication Critical patent/MA38699A1/fr
Publication of MA38699B1 publication Critical patent/MA38699B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique qui comprend un inhibiteur de hmg-coa réductase, en particulier une statine et l'acide acétylsalicylique d'une manière à rendre minimale l'interaction de l'acide acétylsalicylique avec la statine, pour l'utilisation dans la prévention ou le traitement de maladies cardiovasculaires.
MA38699A 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires MA38699B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (fr) 2013-06-06 2013-06-06 Formulation orale pour le traitement de maladies cardiovasculaires
PCT/EP2014/061735 WO2014195421A1 (fr) 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires

Publications (2)

Publication Number Publication Date
MA38699A1 MA38699A1 (fr) 2017-01-31
MA38699B1 true MA38699B1 (fr) 2017-09-29

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38699A MA38699B1 (fr) 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires

Country Status (42)

Country Link
US (1) US10617699B2 (fr)
EP (3) EP2810644A1 (fr)
JP (1) JP6151854B2 (fr)
KR (1) KR101839665B1 (fr)
CN (2) CN104224804A (fr)
AP (1) AP2015008882A0 (fr)
AR (1) AR096350A1 (fr)
AU (1) AU2014276883B2 (fr)
BR (1) BR112015030350B1 (fr)
CA (1) CA2912350C (fr)
CL (1) CL2015003561A1 (fr)
CR (1) CR20150635A (fr)
CU (1) CU24326B1 (fr)
CY (1) CY1118766T1 (fr)
DK (1) DK2986281T3 (fr)
DO (1) DOP2015000296A (fr)
EA (1) EA028969B1 (fr)
EC (1) ECSP15050273A (fr)
ES (1) ES2620078T3 (fr)
GE (1) GEP201706743B (fr)
HK (1) HK1204562A1 (fr)
HU (1) HUE033458T2 (fr)
IL (1) IL242569B (fr)
MA (1) MA38699B1 (fr)
MD (1) MD4475C1 (fr)
MX (1) MX347801B (fr)
MY (1) MY181272A (fr)
NI (1) NI201500171A (fr)
NZ (1) NZ714707A (fr)
PE (1) PE20160051A1 (fr)
PH (1) PH12015502706B1 (fr)
PL (1) PL2986281T3 (fr)
PT (1) PT2986281T (fr)
RS (1) RS55786B1 (fr)
SA (1) SA515370243B1 (fr)
SG (1) SG11201509353QA (fr)
SI (1) SI2986281T1 (fr)
TN (1) TN2015000501A1 (fr)
TW (1) TWI630928B (fr)
UA (1) UA113806C2 (fr)
WO (1) WO2014195421A1 (fr)
ZA (1) ZA201508452B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3283058T3 (da) * 2015-04-16 2023-02-13 Novartis Ag Ribociclib-tablet
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
EP4299063B1 (fr) 2022-06-30 2024-05-01 Ferrer Internacional, S.A. Capsules à avaler comprenant des comprimés d'atorvastatine présentant un profil de dissolution et une biodisponibilité adaptés

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
AU570021B2 (en) 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0904082A4 (fr) * 1996-04-17 2001-09-26 Merck & Co Inc Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
IL150850A0 (en) 2000-02-10 2003-02-12 Bpsi Holdings Inc Enteric coating compositions containing acrylic resin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (fr) 2003-03-10 2004-09-23 Bayer Healthcare Ag Preparations combinees d'acide acetylsalycilique pour la prevention primaire de maladies cardiovasculaires
CN1822820A (zh) * 2003-07-28 2006-08-23 雷迪实验室有限公司 心血管疾病的治疗和预防
ES2395724T3 (es) 2003-08-20 2013-02-14 Shionogi & Co., Ltd. Nueva composición de recubrimiento
BRPI0417017A (pt) 2003-11-26 2007-02-21 Novartis Ag compostos orgánicos
CA2571447A1 (fr) * 2004-06-28 2006-01-05 Howard J Smith & Associates Pty Ltd Composition et procede pour le traitement et la prevention de l'atherosclerose
JP2008532983A (ja) 2005-03-11 2008-08-21 シュペーデル・エクスペリメンタ・アーゲー レニン阻害剤として有用な複素環置換アルカンアミド
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
US20120015032A1 (en) 2007-08-13 2012-01-19 Hanall Pharmaceutical Company, Ltd. Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
US8753680B2 (en) * 2008-03-28 2014-06-17 Ferrer Internacional S.A. Capsule for the prevention of cardiovascular diseases
CN102480954B (zh) * 2009-02-11 2015-03-18 卡帝拉药物有限公司 用于动脉粥样硬化的稳定的药物组合物
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
KR20120130078A (ko) 2009-11-09 2012-11-28 메디비르 아베 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
MX347801B (es) 2017-05-15
GEP201706743B (en) 2017-09-25
IL242569B (en) 2018-12-31
AU2014276883A1 (en) 2015-11-26
EA201600012A1 (ru) 2016-07-29
AR096350A1 (es) 2015-12-23
EP2986281A1 (fr) 2016-02-24
MA38699A1 (fr) 2017-01-31
WO2014195421A1 (fr) 2014-12-11
KR101839665B1 (ko) 2018-03-16
TW201536357A (zh) 2015-10-01
BR112015030350A2 (pt) 2017-07-25
CU20150173A7 (es) 2016-06-29
NI201500171A (es) 2019-05-07
US10617699B2 (en) 2020-04-14
PH12015502706A1 (en) 2016-03-14
MD4475B1 (ro) 2017-04-30
AP2015008882A0 (en) 2015-11-30
PL2986281T3 (pl) 2017-06-30
CA2912350A1 (fr) 2014-12-11
MD4475C1 (ro) 2017-11-30
PT2986281T (pt) 2017-03-29
US20160106763A1 (en) 2016-04-21
AU2014276883B2 (en) 2017-04-20
NZ714707A (en) 2019-04-26
ECSP15050273A (es) 2017-07-31
CN104224804A (zh) 2014-12-24
TWI630928B (zh) 2018-08-01
CL2015003561A1 (es) 2016-06-10
CA2912350C (fr) 2017-04-04
MX2015015753A (es) 2016-08-03
CY1118766T1 (el) 2017-07-12
DK2986281T3 (en) 2017-04-03
HUE033458T2 (en) 2017-12-28
EA028969B1 (ru) 2018-01-31
HK1204562A1 (en) 2015-11-27
EP2986281B1 (fr) 2016-12-21
JP2016520135A (ja) 2016-07-11
JP6151854B2 (ja) 2017-06-21
TN2015000501A1 (en) 2017-04-06
CU24326B1 (es) 2018-03-13
EP3175849A1 (fr) 2017-06-07
SA515370243B1 (ar) 2016-09-19
ES2620078T3 (es) 2017-06-27
KR20160014622A (ko) 2016-02-11
PH12015502706B1 (en) 2016-03-14
CN113143888A (zh) 2021-07-23
DOP2015000296A (es) 2016-12-30
EP2810644A1 (fr) 2014-12-10
ZA201508452B (en) 2017-02-22
UA113806C2 (xx) 2017-03-10
PE20160051A1 (es) 2016-01-25
SI2986281T1 (sl) 2017-07-31
SG11201509353QA (en) 2015-12-30
MD20160001A2 (ro) 2016-05-31
MY181272A (en) 2020-12-21
CR20150635A (es) 2016-06-10
BR112015030350B1 (pt) 2022-11-29
RS55786B1 (sr) 2017-07-31

Similar Documents

Publication Publication Date Title
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
BR112013008140A2 (pt) "compostos imidazotriazinona".
MA45450B1 (fr) Formulations d'anticorps anti-cd19
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
MA34724B1 (fr) Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA34709B1 (fr) Compositions pharmaceutiques
CO2020015124A2 (es) Anticuerpo anti-tlr7 humano
MA41809B1 (fr) Biotine pour le traitement de la sclérose latérale amyotrophique
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
FR3061021B1 (fr) Antagoniste specifique de tlr4 dans le traitement du myelome multiple
FR3040303B1 (fr) Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
MA34232B1 (fr) Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation
MA55298A (fr) Compositions pharmaceutiques contenant des anticorps anti-lingo-1
MA44728A (fr) Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA40375A1 (fr) Anticorps humains contre l'hémagglutinine de la grippe